Last reviewed · How we verify
sodium bicarbonate 8.4%
Sodium bicarbonate acts as a systemic alkalinizing agent that increases blood pH and bicarbonate concentration to counteract metabolic acidosis.
Sodium bicarbonate acts as a systemic alkalinizing agent that increases blood pH and bicarbonate concentration to counteract metabolic acidosis. Used for Metabolic acidosis, Hyperkalemia (adjunctive treatment), Tricyclic antidepressant overdose.
At a glance
| Generic name | sodium bicarbonate 8.4% |
|---|---|
| Sponsor | University of Baghdad |
| Drug class | Alkalinizing agent |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Sodium bicarbonate dissociates in solution to provide bicarbonate ions (HCO3−) that buffer excess hydrogen ions (H+) in the bloodstream, raising pH and correcting acidemia. It is commonly used intravenously to treat severe metabolic acidosis, hyperkalemia, and certain drug overdoses. The 8.4% formulation is a concentrated solution typically administered in acute care settings.
Approved indications
- Metabolic acidosis
- Hyperkalemia (adjunctive treatment)
- Tricyclic antidepressant overdose
- Aspirin overdose
Common side effects
- Hypokalemia
- Metabolic alkalosis
- Hypernatremia
- Phlebitis (at injection site)
- Hypocalcemia
Key clinical trials
- SODium BICarbonate for Metabolic Acidosis in the ICU (PHASE3)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
- Use of Preoperative Sodium Bicarbonate Among Women With Obstructed Labor (PHASE3)
- Evaluating the Clinical Effectiveness of Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury (PHASE4)
- Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial (PHASE1, PHASE2)
- Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery (PHASE3)
- The Effectiveness of Intracuff Dexmedetomidine in Preventing Postoperative Sore Throat Following Prone Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium bicarbonate 8.4% CI brief — competitive landscape report
- sodium bicarbonate 8.4% updates RSS · CI watch RSS
- University of Baghdad portfolio CI